![Thomas Zindrick](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Zindrick
Vorstandsvorsitzender bei
GENELUX CORPORATION
Vermögen: 2 Mio $ am 31.05.2026
Profil
Thomas D.
Zindrick is Chairman, President & Chief Executive Officer at Genelux Corp.
since 2023 and Executive Vice Chairman at Aeromics, Inc. since 2018.
Former roles include Director at DNX Biopharmaceuticals, Inc. from 2014 to 2020, Director at Amitech Therapeutic Solutions, Inc. from 2014 to 2021, Attorney at The Dow Chemical Co., and Vice President & Associate General Counsel at Amgen, Inc. from 2008 to 2009.
Education includes undergraduate studies at North Central College and graduate studies at the University of Illinois College of Law.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GENELUX CORP. 1,19 % | 11.05.2026 | 532.051 ( 1,19 % ) | 2 Mio $ | 31.05.2026 |
Aktive Positionen von Thomas Zindrick
| Unternehmen | Position | Beginn |
|---|---|---|
| GENELUX CORPORATION | Vorstandsvorsitzender | 28.05.2014 |
Aeromics, Inc.
 Aeromics, Inc. BiotechnologyHealth Technology Operates preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema in stroke | Direktor/Vorstandsmitglied | 16.08.2018 |
Ehemalige bekannte Positionen von Thomas Zindrick
| Unternehmen | Position | Ende |
|---|---|---|
Amitech Therapeutic Solutions, Inc | Vorstandsvorsitzender | 01.02.2021 |
DNX Biopharmaceuticals, Inc.
 DNX Biopharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Develops therapeutic proteins for the treatment of patients with life-long diseases | Direktor/Vorstandsmitglied | 01.03.2020 |
| AMGEN INC. | Compliance Officer | 01.01.2008 |
| DOW CHEMICAL COMPANY (THE) | Corporate Officer/Principal | - |
Ausbildung von Thomas Zindrick
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
92
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
The Dow Chemical Co.
 The Dow Chemical Co. Chemicals: Major DiversifiedProcess Industries Manufactures specialty additives, modifiers and plastic polyethylene products | Process Industries |
Genelux Corp.
 Genelux Corp. Pharmaceuticals: MajorHealth Technology Manufactures and markets drugs and virus strains solutions | Health Technology |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Operates preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema in stroke | Health Technology |
North Central College
 North Central College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois College of Law
 University of Illinois College of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
DNX Biopharmaceuticals, Inc.
DNX Biopharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Develops therapeutic proteins for the treatment of patients with life-long diseases | Commercial Services |
Amitech Therapeutic Solutions, Inc |
